Nsabp Protocol B 59 GBG 96 Gepardouze
Research payments
$108,115,064
Through program year 2024, $108,115,064 in research payments was reported against Nsabp Protocol B 59 GBG 96 Gepardouze, across 500 payments, paid by Genentech, Inc..
- Paid by
- Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $5,587,435 | 421 |
| 2023 | Research | $16,338,224 | 2 |
| 2022 | Research | $22,804,478 | 16 |
| 2021 | Research | $22,837,819 | 26 |
| 2020 | Research | $20,454,243 | 20 |
| 2019 | Research | $20,092,866 | 15 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jay Andersen Lawrence, KS Named on 190 payments
- Marcus Braun Vancouver, WA Named on 146 payments
- Norman Wolmark Pittsburgh, PA Named on 60 payments
- Vibha Thomas Littleton, CO Named on 46 payments
- Amy Irwin Philadelphia, PA Named on 11 payments
- Karen Tedesco Amsterdam, NY Named on 8 payments
- Paula Ryan Durham, NC Named on 6 payments
- Miho Teruya Eugene, OR Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.